Academic Journal
Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors.
| Τίτλος: | Definitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for intact breast tumors. |
|---|---|
| Συγγραφείς: | Lischalk JW; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Chen H; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Repka MC; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Campbell LD; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Obayomi-Davies O; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Kataria S; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Kole TP; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Rudra S; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia., Collins BT; Department of Radiation Medicine, Georgetown University Hospital, Washington, District of Columbia. |
| Πηγή: | Advances in radiation oncology [Adv Radiat Oncol] 2018 Jun 11; Vol. 3 (3), pp. 447-457. Date of Electronic Publication: 2018 Jun 11 (Print Publication: 2018). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101677247 Publication Model: eCollection Cited Medium: Print ISSN: 2452-1094 (Print) Linking ISSN: 24521094 NLM ISO Abbreviation: Adv Radiat Oncol Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Philadelphia, PA] : Elsevier Inc., [2016]- |
| Περίληψη: | Purpose: Few definitive treatment options exist for elderly patients diagnosed with early stage breast cancer who are medically inoperable or refuse surgery. Historical data suggest very poor local control with hormone therapy alone. We examined the dosimetric feasibility of hypofractionated radiation therapy using stereotactic ablative radiotherapy (SABR) and proton beam therapy (PBT) as a means of definitive treatment for early stage breast cancer. Methods and Materials: Fifteen patients with biopsy-proven early stage breast cancer with a clinically visible tumor on preoperative computed tomography scans were identified. Gross tumor volumes were contoured and correlated with known biopsy-proven malignancy on prior imaging. Treatment margins were created on the basis of set-up uncertainty and image guidance capabilities of the three radiation modalities analyzed (3-dimensional conformal radiation therapy [3D-CRT], SABR, and PBT) to deliver a total dose of 50 Gy in 5 fractions. Dose volume histograms were analyzed and compared between treatment techniques. Results: The median planning target volume (PTV) for SABR, PBT, and 3-dimensional CRT was 11.91, 21.03, and 45.08 cm3, respectively, and were significantly different (P < .0001) between treatment modalities. Overall target coverage of gross tumor and clinical target volumes was excellent with all three modalities. Both SABR and PBT demonstrated significant dosimetric improvements, each in its own unique manner, relative to 3D-CRT. Dose constraints to normal structures including ipsilateral/contralateral breast, bilateral lungs, and heart were all consistently achieved using SABR and PBT. However, skin or chest wall dose constraints were exceeded in some cases for both SABR and PBT plans and was dictated by the anatomic location of the tumor. Conclusions: Definitive hypofractionated radiation therapy using SABR and PBT appears to be dosimetrically feasible for the treatment of early stage breast cancer. The anatomical location of the tumor relative to the skin and chest wall appears to be the primary limiting dosimetric factor. |
| References: | Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):846-55. (PMID: 26104938) Eur J Cancer. 2005 Mar;41(5):779-85. (PMID: 15763655) Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1751-7. (PMID: 4044337) Radiother Oncol. 2012 Jul;104(1):1-10. (PMID: 22682540) Radiother Oncol. 2011 Aug;100(2):282-8. (PMID: 21367477) Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):71-8. (PMID: 19409733) Br J Surg. 2014 Oct;101(11):1397-404. (PMID: 25088709) Radiother Oncol. 1989 Dec;16(4):253-67. (PMID: 2616812) J Clin Oncol. 2007 May 10;25(14):1882-90. (PMID: 17488987) Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):196-205.e2. (PMID: 28586960) N Engl J Med. 2002 Oct 17;347(16):1233-41. (PMID: 12393820) Br J Surg. 2004 Jun;91(6):699-704. (PMID: 15164437) N Engl J Med. 2004 Sep 2;351(10):971-7. (PMID: 15342805) Tech Vasc Interv Radiol. 2013 Dec;16(4):269-76. (PMID: 24238382) Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1290-6. (PMID: 19395195) Radiology. 2012 Aug;264(2):597-605. (PMID: 22692040) N Engl J Med. 2004 Sep 2;351(10):963-70. (PMID: 15342804) Med Phys. 2010 Aug;37(8):4078-101. (PMID: 20879569) Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):418-24. (PMID: 26254680) J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100. (PMID: 17603311) Eur J Cancer. 1990;26(6):674-9. (PMID: 2168190) Br J Cancer. 2007 Apr 10;96(7):1025-9. (PMID: 17285133) Front Oncol. 2016 May 23;6:129. (PMID: 27242967) Radiother Oncol. 1988 Dec;13(4):267-76. (PMID: 3217542) Eur J Cancer. 2013 Feb;49(3):545-52. (PMID: 22959185) |
| Entry Date(s): | Date Created: 20180912 Latest Revision: 20220321 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6128030 |
| DOI: | 10.1016/j.adro.2018.05.002 |
| PMID: | 30202812 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2452-1094 |
|---|---|
| DOI: | 10.1016/j.adro.2018.05.002 |